Telix Pharmaceuticals has completed a strategic manufacturing agreement with global radiopharmaceuticals manufacturer Global Medical Solutions (GMS) to manufacture and supply finished unit doses of its Molecularly Targeted Radiation (MTR) products for its ongoing clinical development programs.
Under the terms of the agreement, GMS will initially manufacture and deliver finished unit doses of Telix’s investigational prostate cancer therapy products to sites in Australia for the company’s two planned clinical trials.
Telix CEO Dr Christian Behrenbruch said the agreement is structured to support the company’s manufacturing needs for further products and incorporates potential future product distribution requirements in the Asia-Pacific region.
“We are pleased to have entered this manufacturing partnership with GMS, which supports both our immediate clinical development activities in Australia as we commence key clinical trials,” Mr Behrenbruch said.
“Our agreement also paves the way for a longer-term product relationship within the region, particularly in ASEAN countries where GMS is strongly positioned in terms of regulatory expertise and market access.”
GMS Senior Vice President Operations and Business Development Shahe Bagerdjian stated:
“We look forward to leveraging our strengths in manufacturing and distribution to support Telix’s development of their lead prostate cancer therapy candidates in these important clinical trials in Australia.
“GMS is committed to expanding access to diagnostic and therapeutic radionuclides in Australia and more broadly in the Asia-Pacific region.
“We are well placed to support Telix to develop and ultimately deliver these products to patients with prostate cancer in need.”
